Research Radartracking 2 published studies · 1 clinical trials · 2 cancer pages · updated Jun 2026Open the Research Map →

Ovarian Carcinosarcoma

A rare, aggressive ovarian cancer with both carcinoma and sarcoma features. Management is individualized and often complex.

Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

Reviewed Jun 2026 · site editor · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed· last updated Jun 2026

Evidence at a glanceNo graded study evidence yet
205 source documents in the Ovarian Carcinosarcoma corpus

last checked June 8, 2026

Treatment map: Ovarian Carcinosarcoma

Open as a full page →

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

53
Interventions
27
Standard of care
5
Tested in people
0
Lab / animal
17
Named in lit.
7
Classes
Standard of care (27) Guideline option (4) Tested in people (5) Lab / animal only (0) Named in the literature (17)

Tested in people, by trial phase: Phase III ×1 · Phase II ×2 · Phase I ×1 · phase not reported ×1

Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
6
—
—
—
4
Radiotherapy
5
—
—
—
—
Chemotherapy
8
—
3
—
3
Targeted therapy
5
3
1
—
6
Immunotherapy
3
1
—
—
3
Repurposed drugs
—
—
1
—
—
Other
—
—
—
—
1

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Established care — detail (31)
Surgery & procedures
Primary cytoreductive surgery
Primary cytoreductive surgery is the cornerstone of management, similar to high-grade epithelial ovarian cancer.
CurativeStandardCurated
Goal: complete or optimal cytoreduction (<1 cm residual disease), as…
Goal: complete or optimal cytoreduction (<1 cm residual disease), as residual tumor volume is the strongest predictor of survival.
CurativeStandardCurated
Hysterectomy with bilateral salpingo-oophorectomy and omentectomy
Hysterectomy with bilateral salpingo-oophorectomy and omentectomy are standard, often with peritoneal biopsies and nodal assessment.
CurativeStandardCurated
In advanced disease, radical debulking (bowel resection, splenectomy,…
In advanced disease, radical debulking (bowel resection, splenectomy, diaphragm stripping) may be required.
CurativeStandardCurated
Interval debulking (surgery after initial chemotherapy)
Interval debulking (surgery after initial chemotherapy) may be considered if complete resection is not feasible at diagnosis.
CurativeStandardCurated
Fertility-sparing surgery
Fertility-sparing surgery is generally not advised due to aggressiveness, except in ultra-rare Stage IA cases with strong patient preference.
CurativeStandardCurated
Radiotherapy
Not routinely used in frontline management, but
Not routinely used in frontline management, but can play a role in symptom control.
—StandardCurated
Pelvic or para-aortic radiation
Pelvic or para-aortic radiation may help with bulky nodal disease or unresectable pelvic recurrence.
—StandardCurated
Stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT)
Stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT) may be considered for oligometastatic disease (bone, brain, or liver lesions).
Advanced / metastaticStandardCurated
Radiation
Radiation can palliate bleeding, pain, or obstruction when systemic therapy options are exhausted.
PalliativeStandardCurated
Use cautiously in heavily pre-treated patients due to marrow reserve…
Use cautiously in heavily pre-treated patients due to marrow reserve and bowel tolerance.
—StandardCurated
Chemotherapy
Platinum/taxane doublet (e.g., carboplatin + paclitaxel)
Platinum/taxane doublet (e.g., carboplatin + paclitaxel) is most commonly used, borrowed from epithelial ovarian cancer protocols.
—StandardCurated
Response rates
Response rates are lower than in pure epithelial ovarian cancer, reflecting sarcomatous resistance biology.
—StandardCurated
Ifosfamide/doxorubicin or gemcitabine/docetaxel regimens
Ifosfamide/doxorubicin or gemcitabine/docetaxel regimens are sometimes considered in sarcoma-predominant or recurrent settings, but evidence is limited.
Advanced / metastaticStandardCurated
Clinical trial enrollment
Clinical trial enrollment is strongly encouraged given limited standard options.
—StandardCurated
Platinum/Taxane (epithelial-leaning)
Most common backbone borrowed from epithelial ovarian cancer; typically carboplatin + paclitaxel. Response rates lower than HGSOC due to sarcomatous resistance.
—StandardCurated
Ifosfamide/Doxorubicin variants (sarcomatous-leaning)
Anthracycline/ifosfamide combinations used in soft-tissue sarcomas; sometimes considered in sarcoma-predominant OCS. Limited evidence, more toxicity, but an option in select cases.
—StandardCurated
Gemcitabine/Docetaxel (sarcoma option) (recurrent/palliative)
Commonly used in uterine and soft-tissue sarcomas; anecdotal use in OCS with sarcomatous dominance or recurrence.
Advanced / metastaticStandardCurated
PARP inhibitor maintenance (contextual) (BRCA/HRD-positive)
Not a backbone per se, but can serve as maintenance in BRCA/HRD-positive patients after platinum response. Resistance often emerges.
MaintenanceStandardCurated
Targeted therapy
PARP inhibitors (e.g., olaparib, niraparib)
PARP inhibitors (e.g., olaparib, niraparib) may be used in BRCA-mutated or HRD-positive tumors, though data in OCS are anecdotal.
—StandardCurated
Bevacizumab (anti-VEGF) has been used in select cases; timing around…
Bevacizumab (anti-VEGF) has been used in select cases; timing around surgery and wound healing is critical.
—StandardCurated
Homologous recombination deficiency (HRD) and BRCA1/2 mutations: when…
Homologous recombination deficiency (HRD) and BRCA1/2 mutations: when present, PARP inhibitors (olaparib, niraparib, rucaparib) may be considered. Evidence in OCS is extrapolated from epithelial ovarian cancer; responses are anecdotal. Resistance often develops through HR restoration mutations.
—Guideline optionCurated
HER2 overexpression/amplification: uncommon but actionable
HER2 overexpression/amplification: uncommon but actionable. Trastuzumab or newer HER2-targeted agents (trastuzumab deruxtecan) could be considered in select cases, usually extrapolated from gastric/breast data.
—StandardCurated
EGFR and related receptor tyrosine kinases: occasionally expressed in…
EGFR and related receptor tyrosine kinases: occasionally expressed in carcinosarcomas. Small-molecule inhibitors have shown activity in other tumors, but OCS data are sparse. Adaptive bypass (PI3K/AKT, MAPK) usually limits durability.
—StandardCurated
VEGF/angiogenesis signaling: bevacizumab has been incorporated in som…
VEGF/angiogenesis signaling: bevacizumab has been incorporated in some regimens for epithelial ovarian cancer and has been tried in OCS. Benefits are context-dependent; risk of wound-healing complications and hypertension requires careful timing.
—StandardCurated
PI3K/AKT/mTOR alterations: reported in some OCS cases. mTOR inhibitor…
PI3K/AKT/mTOR alterations: reported in some OCS cases. mTOR inhibitors (everolimus, temsirolimus) and PI3K inhibitors are under study in basket trials. Resistance often emerges via pathway redundancy (MAPK cross-talk).
—Guideline optionCurated
Adoptive T-cell therapy, bispecific antibodies, and oncolytic viruses
Adoptive T-cell therapy, bispecific antibodies, and oncolytic viruses are experimental but conceptually relevant given the tumor’s immune-evasive biology.
—Guideline optionCurated
Immunotherapy
Immunotherapy (PD-1/PD-L1 inhibitors)
Immunotherapy (PD-1/PD-L1 inhibitors) is investigational; may be considered if MSI-H, dMMR, or high TMB is documented.
—StandardCurated
MSI-high, dMMR, or TMB-high tumors: these subsets
MSI-high, dMMR, or TMB-high tumors: these subsets may qualify for PD-1 blockade (e.g., pembrolizumab) under tumor-agnostic approvals. Such cases are rare in OCS, but dramatic responses are occasionally reported.
—StandardCurated
PD-1/PD-L1 expression: variable across OCS
PD-1/PD-L1 expression: variable across OCS; may guide trial eligibility. Monotherapy responses tend to be modest; combination approaches (chemo + checkpoint blockade, or dual checkpoint strategies) may be more effective.
—StandardCurated
Combination approaches (e.g., PARP + PD-1 blockade, anti-angiogenic +…
Combination approaches (e.g., PARP + PD-1 blockade, anti-angiogenic + checkpoint inhibitors) may overcome resistance mechanisms and are being explored in clinical trials.
—Guideline optionCurated

Established care shown from OncoForge editorial curation · reviewed September 12, 2025 — authoritative citations (NCI PDQ / FDA) are being added.

Supportive care (22)
  • Pain management: multimodal approach (opioids, neuropathic agents like gabapentin, NSAIDs if safe). Consider palliative care input early for optimization.
  • Nausea/vomiting: 5-HT3 antagonists, NK1 inhibitors, dexamethasone; complementary approaches include ginger, acupuncture, and olanzapine in refractory cases.
  • Ascites management: paracentesis for comfort; indwelling catheters or albumin support for recurrent fluid accumulation.
  • Bowel obstruction: dietary modification, anti-motility or pro-motility drugs (case-specific), stents, or surgical diversion in select cases.
  • Nutritional optimization: early dietitian involvement to preserve weight, muscle mass, and protein intake; address cachexia proactively.
  • Consider specialized diets (ketogenic, fasting-mimicking) only in coordination with oncology to avoid malnutrition.
  • Oral supplementation: vitamin D, omega-3 fatty acids, and probiotics may support resilience, but timing with chemo is critical.
  • Physical therapy and mobility support: maintain baseline function, reduce fall risk, and preserve independence.
  • Prehabilitation (before surgery) and rehabilitation (after surgery/chemo) can improve tolerance of aggressive treatment.
  • Fatigue management: graded exercise, sleep hygiene, mindfulness strategies; screen for anemia or thyroid dysfunction.
  • Psychological support: counseling, peer support groups, or integrative practices (meditation, music therapy).
  • Spiritual care: chaplaincy or faith-based support can improve coping and quality of life.
  • Family/caregiver support: education on prognosis, treatment side effects, and home care planning.
  • Oral mucositis prevention: photobiomodulation (low-level laser), glutamine, or cryotherapy during infusion.
  • Skin care: barrier creams, antifungal powders, and wound care support for radiation or chemo-induced dermatitis.
  • Peripheral neuropathy: consider acupuncture, cryotherapy on hands/feet during taxane infusions, and supplements like alpha-lipoic acid or B-vitamins (if no contraindications).
  • Early palliative care involvement improves quality of life, reduces ER visits, and aligns treatment intensity with patient goals.
  • Hospice transition: should be considered when disease-directed therapy no longer provides benefit or is intolerable.
  • Advance care planning: proactive discussion of goals, advance directives, and treatment preferences to guide care.
  • Sleep support: melatonin, relaxation techniques, or non-habit-forming sleep aids as appropriate.
  • Financial navigation: oncology social worker assistance for medication costs, travel, or disability paperwork.
  • Complementary therapies: massage, aromatherapy, yoga, and mindfulness practices—integrated carefully with medical oversight.
Investigational & adjunct compounds — detail (22)
Phase III trial (1)
platinum-based chemotherapy
Phase II trial (2)
cyclosporin Atrabectedin
Phase I trial (1)
CNTO 95
Tested in people (1)
chemotherapy
Named in the literature
PLAPeribulincarboplatin/paclitaxelifosfamide-paclitaxelniraparibtrastuzumab deruxtecanHER2-directed therapyelimusertibfolate receptor alphavascular endothelial growth factor inhibitorspembrolizumabWT1 mRNA-loaded dendritic cell immunotherapysolitomabcytoreductive surgeryhyperthermic intraperitoneal chemotherapycardiophrenic lymph node resectionsynthetic arterial graft reconstruction

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Living document — last change June 8, 2026: Cancer page updated.

Key points

  • Overview: Ovarian carcinosarcoma is a rare, highly aggressive ovarian malignancy with both carcinomatous and sarcomatous components. It is often diagnosed at an advanced stage in postmenopausal women and is associated with poor prognosis.
  • Epidemiology: Ovarian carcinosarcoma is a rare ovarian malignancy that is usually diagnosed in postmenopausal women, often in the sixth or seventh decade of life. Many reports describe advanced-stage disease at diagnosis, with frequent abdominal or pelvic symptoms and ascites.
  • Standard management: Standard management of ovarian carcinosarcoma is centered on cytoreductive surgery, with adjuvant platinum-based chemotherapy commonly used afterward. Across reviews, management is often described as extrapolated from epithelial ovarian cancer because randomized data and standardized guidelines are limited.
  • Prognosis: Ovarian carcinosarcoma is consistently described as an aggressive cancer with generally poor prognosis, frequent recurrence, and median survival often under 2 years. Across studies, outcome is most often linked to stage and the extent of surgical resection, with some reports also noting effects of chemotherapy and other clinical factors.

10 sections — tap any heading to expand its cited detail. Key points are above.

OverviewOvarian carcinosarcoma is a rare, highly aggressive ovarian malignancy with both carcinomatous and sarcomatous components. It is often diagnosed at an advanced stage in postmenopausal women and is associated with poor prognosis.12 points
EpidemiologyOvarian carcinosarcoma is a rare ovarian malignancy that is usually diagnosed in postmenopausal women, often in the sixth or seventh decade of life. Many reports describe advanced-stage disease at diagnosis, with frequent abdominal or pelvic symptoms and ascites.13 points
  • Ovarian carcinosarcoma is reported as about 1% to 4% of ovarian cancers, ovarian tumors, or ovarian malignancies in multiple sources; some sources give narrower estimates of 1% to 2%, 1% to 3%, 2%, or less than 1%. [22][3][2][4][24][91][25][27][96][28][35][37][38][40][41][42][43][20][98][16][5][67][99][100][18]
  • In a Korean registry study, ovarian carcinosarcoma accounted for 1.5% of epithelial ovarian cancers, with an age-standardized incidence rate of 0.064 per 100,000 women and an annual percent change of 5.86. [101]
  • One systematic review reported the highest incidence age as 60 to 65 years and found that 82% of reported patients were menopausal; other cited sources describe ovarian carcinosarcoma as occurring mainly or most commonly in postmenopausal or elderly women, including with a peak in the sixth decade. [21][8][6][4][25][26][35][12][102][62][5][72][18][77][79]
  • Most patients were menopausal in one systematic review. [21]
  • Sources describe ovarian carcinosarcoma/OMMMT as often presenting at advanced stage. One systematic review reported 59.64% of patients in FIGO stage III, another review said the majority present at advanced stages (often exceeding 60%), and one series reported 70% with FIGO stage III-IV disease. [21][4][25][26][8][34][101][30][46][51][103][104][54][13][59][57][62][11][61][15][9][5][105][67][47]
  • Sources report abdominal pain as the most common symptom in one systematic review. Other cited case reports/reviews mention pelvic or abdominal pain, bloating, compression symptoms, pelvic mass, lower abdominal pain, increased abdominal circumference, and abdominal distension. [21][8][11][15][63][9][72][73][100]
  • In one ultrasound series, 67/91 patients were symptomatic and pain was the most common complaint; bilateral lesions were observed in 46/91 patients. [94]
  • One review states that up to 90% of ovarian carcinosarcomas have disease spread beyond the ovary. The cited sources do not support the added statement that this usually involves the peritoneum or that more than half present with metastatic disease at diagnosis. [45][72][59]
  • In one comparative study, 67% of patients with ovarian carcinosarcoma had lymph node metastasis. [106]
  • In one population-based analysis, 1,763 of 27,737 ovarian tumors were carcinosarcomas, and in one institutional cohort, 11 of 822 ovarian cancer patients had ovarian carcinosarcoma histology. [46][41]
  • In one SEER analysis, 924 of 3683 women had ovarian carcinosarcoma, and in another SEER analysis, women with ovarian carcinosarcoma had a worse five-year disease-specific survival rate than women with high grade papillary serous ovarian carcinoma. [107][108]
  • In one retrospective series, the mean overall survival was 15.4 months, and another review reported a median survival of 18 months and a 5-year survival rate of only 8%. [109][82][12]
  • One review states that fewer than 400 cases of primary ovarian carcinosarcoma had been reported in the English literature, and another describes only a few cases reported in Taiwan. [93][110]
Key biomarkersOvarian carcinosarcoma commonly shows TP53 abnormalities and may also show homologous recombination repair alterations, HER2 expression, and other recurrent molecular changes. Reported biomarkers include serum CA125 and several immunohistochemical markers across epithelial and sarcomatous components.44 points
  • CA125 was abnormal in 88.68% of patients with recorded CA125 status in the systematic review, and serum CA-125 is reported in case reports and reviews as elevated in some patients or in the majority of cases. [21][102][60][59][17]
  • One retrospective series reported elevated CA125 in 4 of 5 patients and elevated CA153 in 3 of 5 patients. [65]
  • TP53 mutations are often detected in OCS, and recent reviews describe OCS as often copy number high with frequent TP53 mutation. [4][24][25][96][29][111][67][14][10]
  • Some OCS tumors harbor homologous recombination pathway alterations such as BRCA1 or BRCA2 mutations, and homologous recombination deficiency has been reported in some ovarian carcinosarcomas. [4][24][58][57][15][14][63]
  • A review states that up to 64% of ovarian carcinosarcomas may harbor homologous recombination deficiency. [4][112]
  • A review states that some ovarian carcinosarcomas have shown limited HER2 expression, and case material has reported HER2 expression in an ovarian carcinosarcoma. [29][63][113]
  • A 2026 case report found identical PIK3CA H1047R and CSF1R alterations in both epithelial and mesenchymal components of one ovarian carcinosarcoma, and interpreted the identical mutations as evidence of a common clonal origin. [2]
  • A pathology study reported SMARCA4 loss of protein expression in all 5 serous/homologous OCS cases it examined. [91]
  • In a single-cell transcriptomics study, epithelial subcluster 4 showed high BRCA1 and TOP2A expression and was related to drug resistance and cell cycle, while mesenchymal subcluster C14 showed elevated CYP24A1, COL23A1, CCK, BMP7, PTN, WIF1, and IGF2 expression. [114]
  • In one molecular study of carcinosarcoma, TP53 mutations were most common, with less common mutations in RB1, MET, KRAS, PTEN, and KIT. [115]
  • Recent reviews report frequent TP53 mutation in ovarian carcinosarcoma and describe it as often copy number high. [96][29]
  • One study found that intraepithelial PD-L1 positivity was associated with positive ascites fluid, and reported no significant difference in PD-L1 expression or CD8+ T lymphocyte counts between intraepithelial and mesenchymal components. [40]
  • A 2024 MRI review states that the Mille-feuille sign can be seen in OCS, and also reports that intratumoral hemorrhage, margin irregularity, unilateral adnexal mass, low ADC values, and low serum CEA levels were more frequent or lower in OCS than in ovarian metastases from colorectal carcinoma. [116]
  • Case reports describe immunohistochemical positivity for markers including WT1, CK7, ER, Pax8, and p53 in ovarian carcinosarcoma tissues or components, and one report identified a TP53 mutation. [15][9][10][16][105]
  • One case report found diffuse p53 and p16 positivity in the STIC, high-grade serous carcinoma component, and chondrosarcoma component, with an identical TP53 mutation in all three components. [17][117]
  • One organoid study reported hyperstaining of p53 protein and a TP53 mutation resulting in deletion of N131. [118]
  • A case report found the carcinomatous component positive for cytokeratin and estrogen receptor and negative for progesterone receptor, while the sarcomatous component was positive for vimentin. [100]
  • One case report found Ki-67 positive in 60% of cells. [100]
  • One case report described strong immunohistochemical reactivities for desmin, cytoplasmic WT1, p16, and vimentin in the sarcomatoid component, and the epithelial component stained for AE1/AE3 cytokeratin, focally for p16 and p53, for nuclear WT1, and weakly for vimentin. [119]
  • A case report found serous tubal intraepithelial carcinoma in both fallopian tubes. [119]
  • In one recurrent case, an increased IGF-II/IGF-I ratio was suggestive of non-islet cell tumor hypoglycemia. [120]
  • One case report found the malignant melanoma focus was positive for S-100, HMB-45, and pan-melanoma cocktail, and negative for synaptophysin and neuron-specific enolase. [121]
  • One case report found ganglioneuroblastoma-like cells were positive for neural markers synaptophysin, S-100 protein, and neuron-specific enolase. [78]
  • One case report found no tumor immunoreactivity to alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and inhibin. [78]
  • In one ovarian MMMT with neuroectodermal differentiation, the neuroectodermal component showed immunoreactivity for glial fibrillary acidic protein, synaptophysin, and S100 protein. [79]
  • In one dog ovarian MMMT, the carcinomatous elements were immunohistochemically positive for cytokeratin AE1/AE3, CK7, vimentin, and estrogen receptors, while the sarcomatous cells were positive for vimentin but negative for cytokeratins and the chondrocytes expressed S-100 protein. [122]
  • DNA ploidy analysis was performed on the various components of one tumor and compared with additional MMMT cases and ovarian immature teratomas. [79]
  • One case report found epithelial membrane antigen positive in a few cells of the sarcomatous component, and the same report described the DNA ploidy pattern of the primary ovarian tumor as diploid, with an additional aneuploid subpopulation in the recurrent tumor. [123]
  • One report found positivity for both neural and epithelial markers in the neuroectodermal cells. [85]
  • In one series, the epithelial component showed epithelial membrane antigen positivity and the fibrosarcomatous area showed vimentin positivity, and S-100 protein was positive in two cases with chondrosarcomatous differentiation. [124]
  • A report of ovarian carcinosarcoma found clonal loss of the wild-type BRCA2 allele and the same somatic TP53 mutation in both histologic components. [83]
  • In one germline study, 20% of patients with ovarian carcinosarcoma had germline pathogenic variants; BRCA1, BRCA2, RAD51C, MSH2, and MSH6 germline pathogenic variants showed biallelic loss in tumors, and all evaluable high-penetrance germline pathogenic variants had biallelic loss. [31]
  • Sources report TP53 abnormalities in ovarian carcinosarcoma, including p53 mutation-pattern staining in one report and a somatic TP53 mutation in another report. [14][10][68]
  • The NEYS cell line produced carcinoembryonic antigen, carbohydrate antigen 19-9, and carbohydrate antigen 125. [125]
  • In one small series, all specimens were negative for CD34, c-erbB-2, estrogen, and progesterone receptor expression, five tumors overexpressed p53, and four specimens demonstrated a positive staining for Ki67. [126]
  • Reactivity for VEGF and CD45RO was observed in four and two tumor specimens, respectively. [126]
  • In one study, p53 protein and Ki67 immunoreactivity were not statistically significant prognostic indicators, and none of the other clinicopathologic factors listed was a statistically significant prognostic indicator. [53]
  • One report found steroid receptor-positive and -negative tumors in both leiomyosarcoma and uterine or ovarian carcinosarcoma, and suggested that steroid receptors should be analyzed in all gynecologic sarcomas. [127]
  • PAS-positive, diastase-resistant hyaline droplets were found in 21 of 22 ovarian malignant mixed mesodermal tumors, including carcinosarcoma, and immunoperoxidase staining for alpha-fetoprotein was consistently negative while droplets and cell cytoplasm reacted strongly with anti-alpha 1-antitrypsin. [128]
  • A review of a human ovarian carcinosarcoma cell line concluded that the tumor line is comprised of epithelial cells capable of multidirectional differentiation, and the parent line JoN showed keratin expression while vimentin was present in both sublines. [129]
  • A mouse model study reported that K-ras mutation and p53 deletion in ovarian surface epithelium gave rise to ovarian lesions and ovarian carcinosarcomas, and that double mutant ovaries formed high-grade, poorly differentiated ovarian carcinosarcomas that were widely metastatic. [130]
  • One study reported higher TUBB3 expression levels in uterine carcinosarcoma cell lines and fresh-frozen tissues than in ovarian carcinosarcoma (P<0.05). [95]
  • In one cell-line and tissue study, TUBB3 expression was significantly higher in primary uterine carcinosarcoma cell lines than in ovarian carcinosarcoma cell lines. [95]
  • In the same study, higher TUBB3 expression levels were detected in uterine versus ovarian fresh-frozen carcinosarcoma tissues (P<0.05). [95]
Biology & pathwaysOvarian carcinosarcoma is a biphasic tumor with malignant epithelial and mesenchymal components, and many sources describe it as a metaplastic carcinoma with clonally related elements. Its histogenesis remains controversial, with conversion, combination, collision, and monoclonal-origin theories all reported, and several studies link sarcomatous differentiation to epithelial-to-mesenchymal transition.52 points
  • No pathognomonic ultrasound sign of ovarian carcinosarcoma was found. [94]
  • All ovarian carcinosarcomas in one ultrasound series contained solid components, and most were described as solid or multilocular-solid. [94]
  • Retrospective image review found irregular margins and inhomogeneous echogenicity of the solid components in all evaluated tumors. [94]
  • In one MRI comparison study, stained-glass appearance, hemorrhage, necrosis, and endometriosis were more common in ovarian carcinosarcoma than in high-grade serous carcinoma. [131]
  • One study found that p53 wild-type tumors were largely driven by KRAS mutations. [90]
  • The sources describe epithelial-to-mesenchymal transition as a proposed mechanism in OCS sarcomatogenesis. [25][91]
  • The study reported higher expression of mesenchymal genes such as VIM, ZEB1, and SNAI1 in the SMARCA4-knockdown group. [91]
  • The same study states that YAP1 is located downstream of the TGFβ and Hippo signaling pathways. [91]
  • The single-cell transcriptomics study identified FGF and PTN signaling as the main pathways contributing to communication between epithelial and mesenchymal cells. [114]
  • The scoping review states that the two most accepted theories of origin are the collision and conversion theories. [27]
  • A review reported evidence of homologous recombination deficiency in ovarian carcinosarcoma. [29]
  • One preclinical study reported that homologous recombination deficiency (HRD) has been demonstrated in >30% of ovarian and uterine carcinosarcomas. [132]
  • One study of ovarian carcinosarcoma evaluated PD-L1 expression and reported that mesenchymal PD-L1-negative expression seemed to be associated with better survival; it also stated that immunotherapy targeting the PD-L1 pathway could be used in OCS. [40]
  • A sequencing study suggested a role for histone H2A and H2B mutations in epithelial-mesenchymal transition and sarcomatous transformation. [133]
  • The mouse model study reported that K-rasG12D overexpression strongly induced cell proliferation, migration, and invasion in ovarian cancer cell lines. [130]
  • One case report proposed that tubal carcinoma may be the origin for ovarian carcinosarcomas through an epithelial-mesenchymal transition. [43]
  • One report states that the fallopian tube has been proposed as an origin for a majority of pelvic or ovarian high-grade serous adenocarcinomas and described adjacent serous tubal intraepithelial carcinoma in its case. [43]
  • One ovarian carcinosarcoma PDX report described EGFR overexpression and amplification, detected EGFR phosphorylation, and implicated angiogenesis and insulin-like growth factor pathways by overexpression of VEGFC and IRS1. [134]
  • The sarcomatous components in one small immunohistochemical series did not express E-cadherin or β-catenin, while carcinomatous components expressed both with reduced expression compared with endometrioid ovarian carcinomas. [135]
  • The same series suggested that cells in the carcinomatous component continuously transform into sarcomatous cells during tumor growth. [135]
  • Extravascular migratory metastasis was observed in an ovarian carcinosarcoma and was proposed as a hitherto unrecognized mechanism of tumor spread in gynecological carcinosarcomas. [136]
  • The perivascular malignant cells in EVMM-positive cases showed more consistent SMA and laminin immunoreactivity than the non-vascular tumor elements. [136]
  • Ovarian carcinosarcomas are described as biphasic tumors with epithelial and mesenchymal components. [46][111][69][72][11]
  • WT1 mRNA-loaded dendritic cell vaccination was reported to be feasible without toxicity in one patient with ovarian carcinosarcoma, and in one report disease progressed after four WT1 mRNA-loaded dendritic cell vaccines. [137]
  • The NEYS cell line study supported the metaplasis theory as the cause of carcinosarcoma. [125]
  • The microscopic analysis suggested the epithelial component to drive the tumor, consistent with the monoclonal theory, and the recurrent setting showed a tendency toward sarcomatous differentiation during disease progression. [138]
  • The 1988 cell-line review concluded that the tumor line is comprised of epithelial cells capable of multidirectional differentiation. [129]
  • STIC is discussed as a proposed precursor lesion for some ovarian carcinosarcomas. [56][59]
  • One case report stated that gene study results suggested the sarcoma component may be differentiated from the cancer component. [16]
  • One review states that carcinosarcomas are carcinomas with epithelial–mesenchymal transition and heterologous differentiation. [17]
  • One case report found diffuse p53 and p16 positivity in STIC, high-grade serous carcinoma, and chondrosarcoma components, and noted evidence suggesting monoclonality. [17][117]
  • One case report suggests that carcinosarcomas may originate from the fallopian tube. [117]
  • The tumors are described as containing both malignant epithelial and mesenchymal elements. [69][72]
  • These tumors are described as mixed, mostly monoclonal tumors. [18]
  • One review states that the predominance of the stromal component aggravates the prognosis. [18]
  • One review notes rare case reports of primitive neuroectodermal tissue among heterologous elements. [77]
  • One case report describes an ovarian carcinosarcoma with malignant neuroectodermal components resembling immature teratoma. [78]
  • One case report describes melanocytic differentiation in an ovarian MMMT. [121]
  • One review suggests that the neuroectodermal component may arise from a separate clone or may evolve at an earlier stage of tumor development. [79]
  • One report states that the tumor phenotype comprised elements derived embryologically from the three germ layers. [139]
  • That report also states that the neoplasm coexisted with, and possibly originated from, a somatic tumor, namely a characteristic endometrioid adenocarcinoma. [139]
  • The same report says all neoplastic tissue patterns present were malignant per se without an apparent gradient of maturation or organoid structures. [139]
  • One report suggested that ovarian carcinosarcoma may arise as progression and clonal evolution of endometrioid adenocarcinoma. [123]
  • The sources describe the histogenesis of ovarian carcinosarcoma as controversial or obscure. [140][123]
  • One report concluded that both histologic elements arose from the same progenitor cell. [83]
  • Another series speculated that ovarian mixed mesodermal tumor might originate from immature multipotential cells of surface epithelium and subcapsular connective tissue of the ovary. [124]
  • One report described the tumor as having prominent neuroectodermal elements mixed with epithelial and mesenchymal elements in an organoid fashion. [85]
  • One report stated that the tumor was heterogeneous on MR imaging and showed very high-intensity on T2-weighted images and iso-intensity on T1-weighted images with visible enhancement. [84]
  • A report noted that MR images provided useful information about the effect of chemotherapy. [141]
  • One source reports an ovarian carcinosarcoma with prominent neuroectodermal differentiation and mixed epithelial and mesenchymal components. [142]
  • The same report describes chondrosarcoma, rhabdomyosarcoma, and malignant neuroectodermal components in the tumor. [142]
  • The sarcomatous portion was described as prominently myxoid and pleomorphic with focal whorling and storiform pattern. [143]
Standard managementStandard management of ovarian carcinosarcoma is centered on cytoreductive surgery, with adjuvant platinum-based chemotherapy commonly used afterward. Across reviews, management is often described as extrapolated from epithelial ovarian cancer because randomized data and standardized guidelines are limited.22 points
  • Reported series describe surgery in most patients, and management commonly included cytoreductive surgery with adjuvant chemotherapy in many cases. [21][95][23][87][88][27][132][37][40][39][42][41][103][48][46][111][61][11][16][5][105][65][64][144][74][145][18][146][82][93][140][110][147][80][148][47][72][70][74][19]
  • Reported surgical management included procedures such as hysterectomy, salpingo-oophorectomy, omentectomy, appendectomy, lymph node dissection, biopsy, and tumor debulking in some cases. [21][16][17][72]
  • A Cochrane review found no trials and no evidence to inform decisions about neoadjuvant or adjuvant chemotherapy and radiotherapy regimens, or chemotherapy alone, for women with ovarian carcinosarcoma. [1]
  • Several reviews state that there is no established, standardized, or consensus treatment plan for ovarian carcinosarcoma, and that recommendations are limited because prospective studies and randomized trials are lacking. [112][32][33][30][149][36][111][67][14][16][5][105][17][64][145][134][15][63][87][1]
  • Management is often described as similar to high-grade serous or other epithelial ovarian cancers, and treatment guidelines are frequently extrapolated from epithelial ovarian cancer experience. [3][4][31][57][61][15][63][14][16][5][144][146][17][134]
  • Sources describe platinum-based chemotherapy as the accepted/mainstay adjuvant treatment for ovarian carcinosarcoma, with carboplatin-paclitaxel commonly used and ifosfamide-containing regimens also reported; one review states carboplatin-paclitaxel is the most commonly used regimen. [112][15][63][9][14][42][45][65][68][57][41][80][110][93][140][70][72][150][151]
  • No visible residual disease after surgery is described as an important prognostic factor, and complete or optimal cytoreduction is associated with improved survival outcomes in several series. [24][4][38][39][40][152][153][82][109][154][46][48][50][155]
  • Sources describe radiotherapy as having an unclear or possible role in ovarian carcinosarcoma/MMMT; one review notes no overall survival benefit but reports decreased local recurrences in carcinosarcomas generally. [70][72][45][54]
  • The FIGO staging system used for ovarian cancer is also used for ovarian carcinosarcoma and related MMMT descriptions. [52][68][67][16][18]
  • One review states that the main treatment is complete surgical resection with staging, followed by postoperative chemotherapy for stage II-IV disease, with chemotherapy also considered for stage I MMMT. [70][18]
  • One review states that adjuvant chemotherapy is typically recommended after debulking surgery, and another describes platinum-based chemotherapy as the current accepted adjuvant treatment and mainstay of adjuvant systemic treatment. [64][42]
  • Sources describe surgery as mandatory in the reported fistulized ovarian carcinosarcoma case, and another case report describes cytoreductive surgery as the treatment performed. [61][11]
  • One review states that the goal of surgery is comprehensive staging in early-stage disease and optimal cytoreduction in advanced-stage disease. [42]
  • One retrospective series reported that early FIGO stage was the only independent prognostic factor for survival, and another reported that feasibility of cytoreductive surgery was a significant prognostic factor in stage III or IV disease. [54][155]
  • One source states that aggressive surgical treatment may play an important role; the cited splenic metastasis case report does not state that complete surgical resection offers the best chance of long-term survival. [146][111]
  • One review states that the sources describe treatment as optimal cytoreduction and chemotherapy. [103]
  • One review states that the mainstay of treatment remains cytoreductive surgical effort for metastatic disease followed by platinum-based chemotherapy. [48]
  • One series reported cytoreductive surgery in 18 of 27 cases. [47]
  • One source states that guidelines for systemic treatment have been difficult to establish because ovarian carcinosarcoma is commonly excluded from prospective clinical trials. [67]
  • One source states that surgery, radiation therapy, and chemotherapy have been used to treat ovarian carcinosarcoma, alone or in combination. [19]
  • Peritoneal cytology is described as a diagnostic and staging tool in ovarian tumors, and one source includes a case of ovarian malignant mixed mullerian tumor in peritoneal washings. [156]
  • Careful correlation of peritoneal cytologic findings, cell-block preparations, and immunocytochemistry with cytohistologic features is described as crucial for correct tumor classification. [156]
Treatments & compounds studiedThe section summarizes 1 00+ studied therapeutics for ovarian carcinosarcoma across chemotherapy, targeted therapy, immunotherapy, hormonal therapy, radiotherapy, procedure/device, repurposed drug, supplement/natural, and other categories.22 treatments

Chemotherapy

Targeted therapy

  • CNTO 95: CNTO 95 was studied in a phase I trial, and one patient with stable ovarian carcinosarcoma had a lesion that became undetectable by FDG-PET, with infusion-related fever reported in the trial. [174]
  • niraparib: Niraparib maintenance therapy has been reported in isolated ovarian carcinosarcoma case material, including a BRCA-wildtype patient treated for more than 20 months; broader PARP inhibitor case series also reported maintenance use with progression-free survival ranging from 13 to 72 months. [4][87][57][113][5]
  • trastuzumab deruxtecan: Trastuzumab deruxtecan was reported in preclinical uterine and ovarian carcinosarcoma models and in case material; a small retrospective gynecologic series including two ovarian carcinosarcoma patients reported overall mixed outcomes, with partial response, stable disease, and progression in the full cohort. [26][175][176][113][57]
  • HER2-directed therapy: HER2-directed therapies, trastuzumab, T-DM1, SYD985, and related antibody-drug conjugates were studied in carcinosarcoma models or discussed for HER2-overexpressed disease. [89][26]
  • elimusertib: Elimusertib was reported in preclinical ovarian and uterine carcinosarcoma models with in vitro sensitivity and in vivo antitumor activity, particularly in HRD tumors. [132]
  • folate receptor alpha: Folate receptor alpha was observed in ovarian carcinosarcoma specimens and described as a potential therapeutic target. [177]
  • vascular endothelial growth factor inhibitors: Vascular endothelial growth factor inhibitors were described in case reports with variable outcomes. [29]

Immunotherapy

  • pembrolizumab: Pembrolizumab was reported in ovarian carcinosarcoma case material, including a heavily pretreated metastatic case with an objective response and another case report describing encouraging outcomes after immunotherapy with emphasis on microsatellite instability testing. [3][62][67]
  • WT1 mRNA-loaded dendritic cell immunotherapy: WT1 mRNA-loaded dendritic cell immunotherapy was reported as feasible without toxicity, but disease progression occurred after vaccination. [137]
  • solitomab: Solitomab showed in vitro cytotoxic activity against EpCAM-positive carcinosarcoma cells. [44]

Repurposed drugs

  • cyclosporin A: Cyclosporin A with carboplatin was studied in a phase II trial in refractory ovarian and fallopian tube cancer, including one ovarian mixed mesodermal tumor, with reported response and thrombocytopenia. [178]

Procedures & devices

  • cytoreductive surgery: Cytoreductive surgery, debulking surgery, optimal cytoreduction, surgical resection, tumorectomy, surgery with arterial reconstruction, cardiopulmonary bypass with IVC tumor/thrombus resection, and other procedures were reported as part of management. [150][162][61][11][165][74][170][98][85][171][140][147][19][172]
  • hyperthermic intraperitoneal chemotherapy: Hyperthermic intraperitoneal chemotherapy after cytoreduction was reported in an advanced-stage ovarian carcinosarcoma cohort; HIPEC agents included carboplatin, cisplatin plus doxorubicin, and melphalan. [179][32][57][113]
  • cardiophrenic lymph node resection: Cardiophrenic lymph node resection was reported in a surgical series that included one ovarian carcinosarcoma case. [162]
  • synthetic arterial graft reconstruction: Individual case material reported synthetic arterial graft reconstruction and postoperative adhesions causing obstructive ileus after para-aortic lymph node dissection. [170][17]

Other

  • PLAP: PLAP immunostaining was detectable in a subset of ovarian carcinosarcomas in one tissue microarray study. [180]
Staging & riskOvarian carcinosarcoma is commonly diagnosed at advanced FIGO stage, especially stage III or IV. FIGO stage is repeatedly described as an important prognostic factor, with earlier-stage disease associated with better survival in several reports.41 points
  • Most tumors were FIGO stage III or IV in one ultrasound series. [94]
  • In one retrospective series, 22.6% of patients were stage IC-II, 67.7% were stage III, and 9.7% were stage IV at diagnosis. [22]
  • In one study, 14% of women with ovarian carcinosarcoma were diagnosed with localized disease. [181]
  • In one study, early diagnosis at stage I was associated with better overall survival. [109]
  • In one study, stage I/II disease had longer progression-free survival and overall survival than stage III/IV disease, although the progression-free survival difference was not statistically significant. [160]
  • The 2006 retrospective series reported FIGO stage IIC, IIIC, and IV disease among ten patients. [161]
  • One series reported 5-year survival rates of 71% for stage I/II, 42% for stage III, and 17% for stage IV disease. [90]
  • In one series, stage was associated with overall survival, with stage I having better survival than stages II, III, and IV. [88]
  • The sources state that OCS is often diagnosed at advanced stage. [4][25][26]
  • The Korean registry study reported localized, regional, and distant stage categories, and patients with localized stage had better survival than those with regional or distant stage. [101]
  • The ovarian carcinosarcoma nomogram study used AJCC stage as a prognostic factor in its model. [33]
  • Ovarian carcinosarcoma is staged according to the FIGO staging of epithelial ovarian tumors, and one nomogram study reported that its nomograms performed better than staging and grading systems. [36][35]
  • Patients in the cited cohort were classified according to the FIGO classification. [41]
  • In one cohort, 18.1% of cases were early stage I or II and 81.8% were advanced stage III or IV. [41]
  • The review states that comprehensive staging is the surgical goal in early-stage disease and optimal cytoreduction is the surgical goal in advanced-stage tumors. [42]
  • In one institutional series, the analyzed patients included stage I, II, III, and IV disease, with most advanced-stage cases being stage III or IV. [151]
  • In one 27-case series, 14 patients had advanced stage disease at presentation. [47]
  • One source reports an advanced stage IIIc ovarian carcinosarcoma cell line. [125]
  • In one case report, ovarian carcinosarcoma metastasized to the spleen as a solitary splenic metastasis. [111]
  • In one case series, the stage distribution was 1 stage I, 6 stage II, 23 stage III, and 1 stage IV. [153]
  • In another series, 80% of patients presented with advanced FIGO stage III or IV disease. [52]
  • In one SEER analysis, the majority of women with OMMMT had advanced-stage disease at diagnosis. [182]
  • One source reports a case classified as advanced stage IIIB (FIGO 2014). [169]
  • One source reports a case of pathologically confirmed stage IVB ovarian carcinosarcoma with multiple solid nodules in both lungs. [11]
  • Sources describe ovarian carcinosarcoma as often presenting with advanced disease, and one source states that more than half of women are diagnosed at an advanced stage. [14][15][9]
  • The sources report peritoneal involvement and lymph node metastases, and one case report describes cutaneous metastasis. [14][10]
  • Some reported cases described peritoneal fluid involvement, including positive peritoneal fluid cytology; one imaging series also reported ascites in all patients. [14][9]
  • One case report classified a tumor as FIGO stage IC. [16]
  • One source reports a case of stage IIIC ovarian carcinosarcoma; another case report describes paraaortic lymph node metastases as the only extrapelvic dissemination but does not state surgical stage IIIA1 in the provided text. [17][118]
  • One case report states that the final diagnosis was ovarian carcinosarcoma with squamous cell carcinoma in the carcinomatous component, stage IIIA1. [64]
  • One source states that ovarian carcinosarcoma is usually managed as high-grade epithelial ovarian cancer. [67]
  • FIGO stage is described as the strongest or most important prognostic factor. [69][72][70]
  • One case report described stage III disease. [70]
  • One review states that the staging system for ovarian and primary peritoneal cancer is also used for MMMT. [18]
  • One report described a unique stage IV complex ovarian carcinosarcoma. [139]
  • Another report described a stage III-C malignant mixed Mullerian tumor. [81]
  • One case report assigned the tumor to FIGO stage IIIc. [93]
  • The imaging review reported FIGO stage IIIb and IV in one patient each and stage IIIc in six patients. [147]
  • One case report assessed the patient as having stage IV disease. [183]
  • One source reports FIGO stage III disease in two long-term survivors. [172]
  • Another source states that these tumors are usually in advanced stages when diagnosed. [19]
PrognosisOvarian carcinosarcoma is consistently described as an aggressive cancer with generally poor prognosis, frequent recurrence, and median survival often under 2 years. Across studies, outcome is most often linked to stage and the extent of surgical resection, with some reports also noting effects of chemotherapy and other clinical factors.85 points
  • The systematic review states that heterologous sarcoma component did not shorten life expectancy. [21]
  • In one retrospective study, ascites and platinum resistance were independent risk factors for decreased overall survival. [154]
  • In one case-control study, median disease-free survival was 29 months for ovarian carcinosarcoma and 27 months for ovarian high-grade serous carcinoma. [154]
  • Ovarian carcinosarcoma has been described as having a poor prognosis. [184][23][4][91][25][26][3][27][92][61][146][80][81][75][120][67][62][56][59][45][49][17][16][5][105]
  • In one database study, the five-year survival rate was 26.63% for ovarian carcinosarcoma and 43.61% for high-grade papillary serous ovarian carcinoma. [184]
  • One study reported that age over 65 years, tumor extension, and platinum-based chemotherapy were independent predictors of survival; in multivariate analysis, age, tumor extension, and uterine versus ovarian carcinosarcoma were independent predictors of overall survival. [181]
  • In one study, bilateral ovarian tumors and metastatic tumors larger than 2 cm were associated with poorer overall survival. [109]
  • In one study, the median overall survival was 19.7 months for the entire cohort. [22]
  • The 2026 organoid study describes ovarian carcinosarcoma as a rare and aggressive tumour type with limited treatment options and poor responses to standard platinum therapy. [3]
  • The 2006 retrospective series reported overall survival rates of 60.0% at 1 year, 40.0% at 2 years, and 20.0% at 5 years. [161]
  • The 2004 GOG cisplatin study reported that 57% of evaluable patients had increasing disease. [159]
  • One retrospective study found that tumor stage, comorbidities, and chemotherapy were associated with overall survival. [88]
  • One retrospective study found that no chemotherapy was associated with worse overall survival than chemotherapy, and that higher comorbidity burden was associated with worse overall survival. [88]
  • One review states that most available retrospective studies support cytoreductive surgery in OCS, with optimal debulking associated with improved survival. [4][42]
  • The scoping review states that prognosis remains poor even when the tumor is localized in the ovary, and that the median survival rate is lower than 2 years. [27]
  • In the Korean registry study, the median overall survival was 39 months and the 5-year overall survival rate was 42.5%. [101]
  • The Korean registry study reported worse survival for distant stage disease than for localized or regional stage disease. [101]
  • Recent reviews and cohort studies describe ovarian carcinosarcoma as having poor survival outcomes. [28][29]
  • In the Scottish cohort, multivariable analysis found ovarian carcinosarcoma associated with poorer outcome than high-grade serous, endometrioid, mucinous, and low-grade serous ovarian carcinoma. [28]
  • In the Scottish cohort, there was no significant difference in survival between clear cell ovarian carcinoma and ovarian carcinosarcoma in multivariable analysis. [28]
  • In one study, late-stage ovarian carcinosarcoma was among the histotypes with the poorest survival. [28]
  • In the SEER-based review, the 5-year cause-specific survival rate for ovarian carcinosarcoma was 25.8%. [30]
  • One review states that the median overall survival for ovarian carcinosarcoma is less than two years. [32][33][67][62][56][75][120]
  • One SEER-based review states that ovarian carcinosarcoma had the lowest 5-year survival rate among gynecologic carcinosarcomas studied. [30]
  • One review states that advanced stage is associated with worse survival in ovarian carcinosarcoma. [32][53][45][107]
  • In the nomogram study, age, grade, tumor size, AJCC stage, surgery, and chemotherapy were independent prognostic factors for overall survival. [33]
  • In the CRS/HIPEC cohort, median progression-free survival was 11.7 months and median overall survival was 21.3 months. [179]
  • A SEER analysis reported that lymphadenectomy was associated with better overall survival in AJCC T2 early ovarian carcinosarcoma, but not in AJCC T1 disease. [39]
  • The same SEER analysis reported no statistically significant survival difference for lymphadenectomy in AJCC T1 disease. [39]
  • The same SEER analysis reported that lymph node metastasis was associated with worse survival in AJCC T2 disease. [39]
  • In one cohort, homologous sarcomatous subtype was associated with better disease-free survival and overall survival than heterologous subtype, and residual disease after surgery was associated with poorer disease-free survival and overall survival. [41]
  • One review states that optimal debulking is associated with improved survival. [42]
  • One comparative study reported 5-year disease-free survival of 19% for ovarian carcinosarcoma and 54% 5-year overall survival. [106]
  • In one institutional series of advanced-stage ovarian carcinosarcoma, the median progression-free survival was 10 months and the median overall survival was 21 months. [151]
  • Prognosis for localized stage disease is poor, with a high risk of local and distant recurrences occurring within 1 year. [45]
  • The survival of women with advanced uterine or ovarian carcinosarcoma is worse than the survival of women with endometrioid or high-grade serous histologies. [45]
  • No improvement in survival rates has been observed in the past few decades, and overall median survival is reported as less than 2 years. [45]
  • In one retrospective series, older age, advanced stage, and residual disease greater than 1 cm after primary cytoreductive surgery were independently associated with worse survival. [152]
  • Advanced stage, suboptimal cytoreduction, and sarcoma predominant tumors are likely to have a worse outcome in ovarian MMMT. [47]
  • In one series, recurrence-free survival was 10.5 months in advanced stage disease compared with 13 months in early stage disease and epithelial predominant tumors. [47]
  • One SEER study reported that survival for both early- and late-stage ovarian carcinosarcoma was inferior to serous tumors. [46]
  • The sources describe ovarian carcinosarcoma as having poor outcome or grim prognosis. [146]
  • One review states that the tumor is associated with an average survival of less than 2 years. [49]
  • In a case-control study, advanced ovarian carcinosarcoma had worse response and survival than serous epithelial ovarian cancer. [146]
  • In a SEER analysis, ovarian carcinosarcoma prognosis was influenced by age, stage, and lymphadenectomy. [107]
  • Median survival was 38 months in one retrospective cohort of 22 patients. [103]
  • Median survival was 46 months for optimally debulked patients and 27 months for suboptimally debulked patients in one retrospective cohort. [103]
  • In one comparison study, the median survival for ovarian carcinosarcoma was 11 months and the hazard ratio for overall survival versus uterine carcinosarcoma was 0.991. [104]
  • Median survival for the entire group was 21 months in one 31-patient series. [153]
  • Median overall survival was 32.9 months in one nine-patient institutional series. [126]
  • Median cause-specific survival was 8.2 months in one prospective series of carcinosarcoma and serous adenocarcinoma comparison, and median progression-free survival was 6.4 months in one prospective series. [166]
  • Residual disease after surgery was associated with decreased overall survival in stage IIIC disease in one series. [153]
  • Bulk residual disease after surgery was associated with worse survival in one retrospective series. [52]
  • Advanced-stage OMMMT had a higher risk of death than advanced-stage high-grade epithelial ovarian cancer in one SEER analysis, and ovarian carcinosarcoma had a significantly worse prognosis than epithelial ovarian cancer in one SEER analysis. [182]
  • One series reported an overall 5-year survival rate of 27.1%. [53]
  • In that series, 5-year survival was 100% for stage I, 31.3% for stage II, 10.9% for stage III, and 0% for stage IV. [53]
  • Low-stage disease, defined as stages I and II, was a significant prognostic factor for survival in one study. [53]
  • One series reported an overall median survival of 247 days, with 40% 1-year survival and 6% 5-year survival. [54]
  • In one retrospective series, stage III or IV disease had a median survival of 18 months and a 5-year survival rate of 8%. [155]
  • Advanced stage appears to be a poor prognostic indicator of survival. [53]
  • Histology, including homologous or heterologous subtype and the grade, type, or percentage of the epithelial component, had no significant impact on survival in one series. [54]
  • One source states that ovarian carcinosarcoma has a poor prognosis. [61]
  • One source states that fistulization to the large intestine worsens prognosis. [61]
  • Sources describe ovarian carcinosarcoma as having a poor prognosis. [63][10]
  • Sources describe ovarian carcinosarcoma as having a very poor or extremely poor prognosis. [16][5][105]
  • One case report described a patient who was followed for six years after surgery and chemotherapy and was in good health; the authors noted long-term disease-free survival. [16]
  • OCS is described as an aggressive tumour with a dismal prognosis. [17]
  • One retrospective series reported that one patient died from recurrence and metastasis, while three patients were alive without obvious recurrence or metastasis during follow-up of 9 to 59 months. [65]
  • One review states that patients are usually given a poor prognosis of under three years. [75]
  • Stage of disease is described as the most important predictor for survival. [77]
  • One review states that heterologous elements have no prognostic effect. [77]
  • One review states that the predominance of the stromal component aggravates the prognosis. [18]
  • One case report describes a patient who died of disease 3 years 10 months after initial treatment. [78]
  • Ovarian malignant mixed müllerian tumors usually yield poor outcomes. [80]
  • These tumors have a generally poor prognosis and often develop recurrent disease. [81]
  • One report describes two patients who were disease-free 2 and 3 years after initial therapy. [148]
  • A case report described no new metastatic lesions on CT scan three months after palliative chemotherapy. [81]
  • One source reported that a patient died from disease 17 months after surgery. [93]
  • A case report described 41 months of remission after aggressive surgical debulking, platinum-containing chemotherapy, and intraoperative radiotherapy. [82]
  • The same report described another 22-month progression-free survival after liposomal doxorubicin and later liposomal doxorubicin/carboplatin, without obvious toxicity. [82]
  • One source states that patients with ovarian malignant mixed müllerian tumor have a median survival of 18 months and a 5-year survival rate of 8%. [82]
  • Long-term survival is described as unusual in ovarian malignant mixed mullerian tumor. [172]
  • One review reports that 77.6% of patients were dead of their disease within 1 year. [19]
  • Limited data suggest that patients treated with surgery and combination chemotherapy survive longer. [19]
  • Two stage III patients in one report had prolonged survival after surgery plus adjuvant therapy, but the report presents these as unusual examples rather than typical outcomes. [172]
Safety & interactionsReported safety findings in ovarian carcinosarcoma are mostly from small trials, case series, and case reports. Toxicities vary by treatment, with hematologic, gastrointestinal, hepatic, renal, and postoperative complications described in several reports.17 points
  • The Cochrane review found no trials, so no safety or efficacy data were analyzed. [1]
  • In the phase III trial, toxicities were similar between paclitaxel-carboplatin and paclitaxel-ifosfamide, except for more hematologic toxicity with paclitaxel-carboplatin and more confusion and genitourinary hemorrhage with paclitaxel-ifosfamide. [157]
  • The phase II study reported that adverse events were comparable across study arms for intermittent relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy. [185]
  • Trabectedin was associated with grade 3-5 neutrophil count decreases and transaminase increases in the phase II trial. [173]
  • In one study, two women did not complete treatment because of rapid disease progression and severe toxicity. [160]
  • The same study states that the combination of anthracycline, alkylating agent, and cisplatin showed a good response rate but also a high toxicity. [160]
  • In the cisplatin study, grade 2 or higher adverse effects included nausea and vomiting, leukopenia, neutropenia, thrombocytopenia, anemia, azotemia, neurotoxicity, fever, and tinnitus. [159]
  • In the cyclosporin A and carboplatin study, the most common grade 3 or 4 toxicity was thrombocytopenia in 22% of patients, and hypertension occurred in 18% during infusion. [178]
  • In the CNTO 95 phase I study, infusion-related fever occurred in one grade III and four grade II episodes among 24 enrolled patients. [174]
  • In the CRS/HIPEC cohort, major complications occurred in 25% of patients, there was no 90-day mortality, and malignant bowel obstruction occurred in 18.7% of patients. [179]
  • WT1 mRNA-loaded dendritic cell vaccination was feasible without toxicity in one report. [137]
  • One case report of non-islet cell tumor hypoglycemia in ovarian carcinosarcoma describes treatment with prednisone, continuous dextrose, and glucagon infusion. [60]
  • One case report described surgical management of ovarian carcinosarcoma with IVC and right atrial extension and noted challenges related to coagulopathy. [98]
  • One case report described postoperative obstructive ileus caused by adhesion between the abdominal aorta and terminal ileum after surgery. [17]
  • One recurrent case report stated that liposomal doxorubicin and later liposomal doxorubicin/carboplatin were given without obvious toxicity. [82]
  • Another case report described acute hepatitis caused by reactivation of hepatitis B virus infection during chemotherapy with adriamycin and cisplatin, and the patient died of hepatic failure two weeks later. [140]
  • One report of o,p'-DDD therapy described side effects including low T4, increased bleeding time, increased substitution requirements for hydrocortisone and fludrocortisone acetate, and periods of hypoadrenocorticism with prerenal uraemia, and the same report states that a reduced mineralocorticoid activity induced by o,p'-DDD was reversed after discontinuation of treatment. [186]
What we don't know yetFor ovarian carcinosarcoma, the literature repeatedly notes that optimal treatment, prognostic factors, and biomarker-guided strategies remain uncertain. Many sources also call for larger prospective studies, randomized trials, and better molecular characterization.18 points
  • Reported chemotherapy regimens have shown mixed results, and the preferred first-line or adjuvant regimen remains unknown. [1][22][41][134][46][49][111][52][55][149][17][18][69][72][39][40][38][37][112]
  • Randomized or well-designed non-randomized studies are still needed to compare treatment modalities and improve current knowledge. [1][54][73]
  • Several sources describe ovarian carcinosarcoma treatment as uncertain or not yet determined, with limited evidence and no unified treatment plan. [30][37][38][39][40][33][16][5][105][17][64][67][18][49][55][111][52][11][61]
  • Sources describe the role of radiotherapy in ovarian carcinosarcoma as needing further study. [52][105][72][27]
  • Sources state that ovarian carcinosarcoma is rare, high-quality evidence is limited, and future prospective studies and clinical trials are needed. [4][37][89][73][68][52][36][32][17][67][15][14]
  • Reviews and case-based reports describe limited prospective evidence for targeted therapies in ovarian carcinosarcoma; PARP inhibitors are discussed mainly as a rationale or in small case reports/series, including some BRCA-mutated and HRD-positive cases. [4][96][187][5]
  • Sources describe ovarian carcinosarcoma prognostic assessment as limited or insufficient, and report proposed prognostic factors that require further study. [87][33][19][57]
  • A 2024 study describes OCS as understudied and investigates molecular events that may drive sarcomatous compartment formation through EMT, including global differences in microRNA profiles between compartments. [25]
  • Case reports suggest a possible relationship between STIC and ovarian carcinosarcoma, but this relationship remains uncertain. [43][56]
  • The effect of chemotherapy on the different components of ovarian carcinosarcoma is largely unknown, and further studies are required to define the value of intraperitoneal chemotherapy. [167][148]
  • No pathognomonic ultrasound sign of ovarian carcinosarcoma was found. [94]
  • The 2023 phase II study reported that the primary end point did not meet statistical significance after multiplicity adjustment. [185]
  • The 2026 retrospective cohort study described its findings as exploratory and hypothesis-generating. [158]
  • A 2026 organoid study describes ovarian carcinosarcoma as a rare, aggressive tumour type with limited treatment options and poor responses to standard platinum therapy. [3]
  • A recent study notes that ovarian carcinosarcoma has been excluded from many pan-histotype ovarian carcinoma studies, limiting understanding of its behavior. [28]
  • One review says the role of radiotherapy and novel therapies needs further study. [27]
  • One case report concludes that further cases need to be accumulated to determine a successful treatment modality. [78]
  • Neuroectodermal differentiation in ovarian MMMTs is exceedingly uncommon, with only a few case reports in the literature. [79]

Sources

Every statement above is drawn from these reviewed sources. This page reports what they describe. Sources last checked June 8, 2026.

  1. Systematic reviewChemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma · 2013
  2. Review articleEndometriosis-Associated Ovarian Carcinosarcoma Featuring Well-Differentiated Adenocarcinoma and Fetal Rhabdomyoma-Like Mesenchymal Components: An Unusual Case Report-With Molecular Analysis · 2026
  3. Review articleHigh-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma · 2026
  4. Review articleRecent Developments in Rare Ovarian Carcinosarcoma: Literature Review and Case Report · 2025
  5. Case reportCase Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma · 2021
  6. Review articleManagement of a rare ovarian carcinosarcoma: A case report and literature review · 2022
  7. Review articleEpithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin · 2022
  8. Review articleTherapeutic Management of Rare Primary Ovarian Neoplasms: Carcinosarcoma, Leiomyosarcoma, Melanoma and Carcinoid · 2021
  9. Case reportPrimary ovarian malignant mixed Müllerian tumor: a rare case report · 2022
  10. Case reportCutaneous metastasis of carcinomatous component of ovarian carcinosarcoma: A case report and review of the literature · 2022
  11. Case reportOvarian carcinosarcoma with lung metastasis characterized by persistent fever: A case report and literature review · 2024
  12. ObservationalRadical surgical cytoreduction in the treatment of ovarian carcinosarcoma · 2014
  13. Case reportStage IVB ovarian carcinosarcoma in BRCA wild-type patients: two case reports of unexpected long-term remission · 2026
  14. Case reportCarcinosarcoma of the ovary: a case report and literature review · 2023
  15. Case reportMetastatic ovarian carcinosarcoma in a patient undergoing in-vitro fertilization: A case report · 2023
  16. Case reportGenetic Analysis and Combined Therapy of Surgery and Chemotherapy for the Progression-Free Survival of a Patient with Ovarian Carcinosarcoma: A Case Report and Literature Review · 2022
  17. Case reportOvarian Carcinosarcoma with Retroperitoneal Para-Aortic Lymph Node Dissemination Followed by an Unusual Postoperative Complication: A Case Report with a Brief Literature Review · 2020
  18. Case reportMalignant mixed Mullerian tumor of the ovary with two cases and review of the literature · 2011
  19. Case reportMalignant mixed mesodermal tumors and carcinosarcoma of the ovary: report of eight cases and review of literature · 1983
  20. Review articlePresence of both Mesenchymal and Carcinomatous Features in an In-vitro Model of Ovarian Carcinosarcoma Derived from Patients' Ascitic Fluid · 2015
  21. Systematic reviewThe clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review · 2022
  22. Clinical trialComparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature · 2018
  23. Review articleMRI Findings of Ovarian Carcinosarcoma: A Retrospective Comparison With Endometrioid Carcinoma · 2026
  24. Review articleGenomics of ovarian cancers and the potential of precision medicine · 2025
  25. Review articleCompartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma · 2024
  26. Review articleMesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression · 2024
  27. Review articleSpotlight on Carcinosarcoma of the Ovary: A Scoping Review · 2024
  28. Review articleOvarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes · 2024
  29. Review articleGenomic and Molecular Characteristics of Ovarian Carcinosarcoma · 2023
  30. Review articleTrends in Gynecologic Carcinosarcoma Based on Analysis of the Surveillance Epidemiology End Result (SEER) Database · 2023
  31. Review articleGermline drivers of gynecologic carcinosarcomas · 2023
  32. Review articleFrontiers of Ovarian Carcinosarcoma · 2023
  33. Review articleEstablishment and validation of a novel nomogram for survival prediction of ovarian carcinosarcoma · 2022
  34. Review articleOvarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma · 2022
  35. Review articleClinical Nomograms for Predicting the Overall Survival and Cancer-specific Survival of patients with Ovarian Carcinosarcoma patients after Primary Surgery · 2021
  36. Review articleDetailed overview on rare malignant ovarian tumors · 2020
  37. Review articleOverall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience · 2019
  38. Review articleOvarian carcinosarcoma: Current developments and future perspectives · 2019
  39. Review articlePrognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma · 2018
  40. Review articleClinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma · 2017
  41. Review articlePrognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma · 2017
  42. Review article"Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities" · 2016
  43. Review articleOvarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma · 2016
  44. Review articleSolitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro · 2015
  45. Review articleGynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma · 2014
  46. Review articleCarcinosarcoma of the ovary: natural history, patterns of treatment, and outcome · 2013
  47. Review articleClinico-pathological spectrum of primary ovarian malignant mixed mullerian tumors (OMMMT) from a tertiary cancer institute: A series of 27 cases · 2013
  48. Review articleCarcinosarcoma of the ovary: a review of the literature · 2012
  49. Review articleCarcinosarcoma of the ovary a review · 2009
  50. Review articleCurrent management of ovarian carcinosarcoma · 2007
  51. Review articleCarcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience · 2007
  52. Review articleCarcinosarcoma of the ovary · 2003
  53. Review articlePrognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases · 2000
  54. Review articleCarcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients · 1995
  55. Review articleCarcinosarcoma of the ovary treated over a 10-year period at the Christie Hospital · 1994
  56. Case reportThe development of ovarian carcinosarcoma from serous tubal intraepithelial carcinoma: an immunohistochemical case report with literature review · 2026
  57. Case reportThe use of PARP inhibitors as maintenance therapy in ovarian carcinosarcoma: A case series · 2025
  58. Case reportBilateral ovarian carcinosarcoma - A rare and aggressive malignancy: Case report · 2025
  59. Case reportOvarian Carcinosarcoma Mimicking Symptoms of Recurrent Diverticulitis: A Case Report · 2024
  60. Case reportInitial Presentation of Ovarian Carcinosarcoma With Non-islet Cell Tumor Hypoglycemia: A Case Report · 2024
  61. Case reportSigmoido-ovarian fistula complicating ovarian carcinosarcoma: a case report · 2024
  62. Case reportOvarian Carcinosarcoma and Response to Immunotherapy · 2023
  63. Case reportDo Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma · 2022
  64. Case reportA rare case of ovarian carcinosarcoma with squamous cell carcinoma · 2019
  65. Case reportPrimitive ovarian carcinosarcoma: a clinical and radiological analysis of five cases · 2020
  66. Case reportOvarian Teratoid Carcinosarcoma Is an Aggressive Tumor of Probable Mullerian Derivation with a Carcinosarcomatous and Mixed Germ-Cell Morphology · 2019
  67. Case reportResponse to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma · 2018
  68. Case reportCauda equina syndrome in an ovarian malignant-mixed müllerian tumor with leptomeningeal spread · 2019
  69. Case reportPrimary Ovarian Malignant Mixed Mullerian Tumour: A Case Report and Brief Review of Literature · 2016
  70. Case reportProlonged survival of a patient with pelvic recurrence of ovarian malignant mixed mullerian tumor after chemoradiotherapy · 2014
  71. Case reportMature Teratoma Associated with Bilateral Ovarian Carcinosarcoma - Accidental Association or Etiopathogenetic Determinism? - Case Report · 2016
  72. Case reportThe Use of Lattice Radiation Therapy (LRT) in the Treatment of Bulky Tumors: A Case Report of a Large Metastatic Mixed Mullerian Ovarian Tumor · 2015
  73. Case reportOvarian carcinosarcoma: a case report, diagnosis, treatment and literature review · 2015
  74. Case reportOvarian carcinosarcoma in a renal transplant recipient. A unique case of a rare tumor · 2014
  75. Case reportCarcinosarcoma of the ovary: case report and literature review · 2012
  76. Case reportA case of bilateral ovarian synchronous tumors (left ovarian serous papillary adenocarcinoma and right ovarian malignant mixed Müllerian tumor) · 2011
  77. Case reportOvarian malignant mixed mullerian tumor with primitive neuroectodermal differentiation: case report with review of the literature · 2011
  78. Case reportMalignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings · 2010
  79. Case reportOvarian malignant mixed mesodermal tumor with neuroectodermal differentiation: a multifaceted evaluation · 2010
  80. Case reportPrimary malignant mixed müllerian tumor of the ovary · 2010
  81. Case reportPancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy · 2006
  82. Case reportExcellent progression-free survival with liposomal doxorubicin for a patient with recurrent ovarian malignant mixed müllerian tumor: case report and literature review · 2004
  83. Case reportCarcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin · 2000
  84. Case reportMR images of ovarian carcinosarcoma · 1999
  85. Case reportTeratoid carcinosarcoma of the ovary with prominent neuroectodermal differentiation · 2001
  86. Case reportComplete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine · 1991
  87. Review articleReal-world experience and prognostic factors in ovarian carcinosarcoma: a single-center retrospective study from China · 2025
  88. Review articleThe impact of demographic, clinical, and treatment factors on overall survival in ovarian carcinosarcomas: a National Cancer Database study · 2025
  89. Review articleSYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression · 2017
  90. Review articleClinicopathologic and Molecular Features of Tubo-Ovarian Carcinosarcomas With an Emphasis on p53 Wild-Type, KRAS-Mutated Tumors · 2026
  91. Review articleLoss of SMARCA4 induces sarcomatogenesis through epithelial-mesenchymal transition in ovarian carcinosarcoma · 2025
  92. Review articleT-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review · 2021
  93. Case reportPrimary ovarian carcinosarcoma: a case report and review of the literature · 2004
  94. Clinical trialImaging in gynecological disease (23): clinical and ultrasound characteristics of ovarian carcinosarcoma · 2022
  95. Clinical trialDifferential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression · 2012
  96. Review articleOvarian carcinosarcomas: p53 status defines two distinct patterns of oncogenesis and outcomes · 2024
  97. Review articleTherapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network · 2022
  98. Case reportSurgical management of ovarian carcinosarcoma with inferior vena cava extension into the right atrium · 2020
  99. Case reportMultiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis · 2018
  100. Case reportCarcinosarcoma of ovary with its various immunohistochemical expression: Report of a rare case · 2015
  101. Review articleIncidence and treatment outcomes of ovarian carcinosarcoma from the national cancer registry of Korea · 2024
  102. Case reportCarcinosarcoma of Uterus and Ovary-Clinical, Morphological, and Immunohistochemical Study of Case Series · 2025
  103. Review articleCarcinosarcoma of the ovary · 2008
  104. Review articleClinical features and outcomes of uterine and ovarian carcinosarcoma · 2006
  105. Case reportOvarian malignant mixed Müllerian tumor: a rare case report from Tanzania · 2020
  106. Review articleUterine and Ovarian Carcinosarcomas: Do They Behave Similarly? · 2017
  107. Review articleOvarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes · 2010
  108. Review articleCarcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis · 2013
  109. Clinical trialPrimary treatment and prognostic factors of carcinosarcoma of the ovary, fallopian tube, and peritoneum: a Taiwanese Gynecologic Oncology Group Study · 2014
  110. Case reportMalignant mixed müllerian tumors of the ovary · 2000
  111. Review articleSolitary splenic metastasis from ovarian carcinosarcoma: a case report · 2011
  112. Review articlePlatinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis · 2025
  113. Case reportResponse of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report · 2023
  114. Review articleSingle-cell transcriptomics reveals tumor landscape in ovarian carcinosarcoma · 2024
  115. Review articleMolecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations · 2024
  116. Review articleUnveiling the mille-feuille sign: a key to diagnosing ovarian carcinosarcoma in addition to ovarian metastasis from colorectal carcinoma on MRI · 2024
  117. Case reportOvarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma With Next-Generation Sequencing Suggesting an Origin From the Fallopian Tube · 2019
  118. Case reportCharacterization of a TP53 Somatic Variant of Unknown Function From an Ovarian Cancer Patient Using Organoid Culture and Computational Modeling · 2020
  119. Case reportOvarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: a case report · 2013
  120. Case reportNon-islet cell tumor hypoglycemia associated with recurrent carcinosarcoma of the ovary · 2013
  121. Case reportMalignant melanoma arising in an ovarian carcinosarcoma: case report and review of the literature · 2011
  122. Case reportBilateral ovarian malignant mixed Mullerian tumor in a dog · 2009
  123. Case reportOvarian carcinoma recurring as carcinosarcoma · 2001
  124. Case reportMixed mesodermal tumor of the ovary: immunohistochemical study with histogenetic consideration · 1993
  125. Review articleEstablishment and characterization of the NEYS cell line derived from carcinosarcoma of human ovary with special reference to the susceptibility test of anticancer drugs · 2009
  126. Review articleClinicopathological features of ovarian carcinosarcomas: a single institution experience · 2005
  127. Review articleEstradiol and progesterone receptors in gynecologic sarcomas · 1984
  128. Review articleOvarian malignant mixed mesodermal tumor: the occurrence of hyaline droplets containing alpha 1-antitrypsin · 1982
  129. Review articleDevelopment and characterization of a human cell line from an ovarian mixed Müllerian tumor (carcinosarcoma) · 1988
  130. Review articleKRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice · 2017
  131. Clinical trialCarcinosarcoma of the ovary: MR and clinical findings compared with high-grade serous carcinoma · 2021
  132. Review articleOvarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor · 2023
  133. Review articleMutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition · 2016
  134. Review articleConventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft · 2015
  135. Review articleExpression of adhesion molecules and the proliferative activity of carcinosarcoma of the ovary · 2014
  136. Review articleExtravascular migratory metastasis in gynaecological carcinosarcoma · 2014
  137. Review articleImmunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma · 2013
  138. Review articleTransition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis · 2003
  139. Case reportMalignant Müllerian mixed tumor of the ovary associated with yolk sac tumor, neuroepithelial and trophoblastic differentiation (teratoid carcinosarcoma) · 2008
  140. Case reportCarcinosarcoma of ovary associated with previous radiotherapy · 2001
  141. Case reportA case of malignant mixed mesodermal tumor (MMMT) of the ovary: MR features before and after chemotherapy · 1999
  142. Case reportMalignant mixed müllerian tumor of the ovary with prominent neuroectodermal differentiation (teratoid carcinosarcoma) · 1990
  143. Case reportMultiple malignancies (squamous cell carcinoma and sarcoma) arising in a dermoid cyst of the ovary · 1981
  144. Case reportExtremely Locally Advanced Ovarian Malignant Mixed Mullerian Tumor in 37-Years-Old Female · 2017
  145. Case reportPrimary ovarian malignant mixed mesodermal tumor: report of four cases · 2014
  146. Review articleCarcinosarcoma of the ovary: a case-control study · 2011
  147. Case reportMalignant mixed müllerian tumor of the ovary: imaging findings · 2001
  148. Case reportComplete cytoreduction combined with early postoperative intraperitoneal chemotherapy for ovarian carcinosarcoma. Report of two cases · 2006
  149. Review articleShould MMMT still be treated with adjuvant taxane-based combination chemotherapy? · 2020
  150. Review articleIntraoperative Radiation Therapy for Gynecologic Malignancies: When Is It Indicated? · 2025
  151. Review articleCarcinosarcoma of the ovary: a single institution experience and review of the literature · 2016
  152. Review articleOvarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival · 2013
  153. Review articleCarcinosarcoma of the ovary-a case series · 2006
  154. Clinical trialCarcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment · 2018
  155. Review articleMalignant mixed müllerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy · 1995
  156. Case reportPeritoneal cytology of uncommon ovarian tumors · 1992
  157. Randomized trialRandomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial · 2022
  158. Clinical trialAssociation of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study · 2026
  159. Clinical trialCisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study · 2004
  160. Clinical trialPlatinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma · 2009
  161. Clinical trialMalignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy · 2006
  162. Review articleCardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study · 2019
  163. Review articleRhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma · 2014
  164. Review articleComplete response with pegylated liposomal doxorubicin as a second-line therapy in metastatic ovarian carcinosarcoma: Significance of assessment of the response by FDG-PET · 2012
  165. Review articleCarcinosarcoma of the ovary: analysis of 13 cases and review of the literature · 2011
  166. Review articleCarcinosarcoma of the ovary: 19 years of prospective data from a single center · 2004
  167. Review articleThe effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract · 1994
  168. Review articleProlonged survival of stage IV malignant mixed Müllerian tumor of the ovary after carboplatin, mesna, ifosfamide, and cis-platin chemotherapy: case report · 1998
  169. Case reportA case of ovarian carcinosarcoma with germline BRCA2 pathogenic variant · 2024
  170. Case reportAggressive Resection of Malignant Paraaortic and Pelvic Tumors Accompanied by Arterial Reconstruction with Synthetic Arterial Graft · 2021
  171. Case reportWhole-body FDG PET/CT in diagnosis of internal mammary nodal metastasis of ovarian carcinosarcoma · 2011
  172. Case reportMalignant mixed mullerian tumors of the ovary. An analysis of two long-term survivors · 1993
  173. Clinical trialEfficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) · 2022
  174. Clinical trialPhase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors · 2007
  175. Review articleReal-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies · 2024
  176. Review articleTrastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression · 2023
  177. Review articleFolate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma · 2023
  178. Clinical trialModulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study · 1996
  179. Review articleOutcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma · 2023
  180. Clinical trialPattern of placental alkaline phosphatase (PLAP) expression in human tumors: a tissue microarray study on 12,381 tumors · 2021
  181. Clinical trialPrognostic determinants in patients with uterine and ovarian carcinosarcoma · 2013
  182. Review articleSurvival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT) · 2004
  183. Case reportBorderline serous cystadenocarcinoma with coexistent angiosarcoma: an unusual form of ovarian carcinosarcoma · 2001
  184. Clinical trialPatterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis · 2016
  185. Randomized trialRelacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study · 2023
  186. Case reportA case of recurrent adrenocortical carcinoma, with observations on long-term o,p'-DDD therapy and complications · 1992
  187. Case reportSuccessful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report · 2024

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
0
Meta-analysis
0
Systematic review
3
Randomized trial
2
Clinical trial
17
Observational
1
Case report
80
Review
102
Preclinical
0
Other
0

Clinical trials in Ovarian Carcinosarcoma

15 ongoing · 21 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.

Completed
11 stopped (terminated / withdrawn / suspended)

Search all trials on ClinicalTrials.gov →

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →

Go deeper

Questions to ask your oncologist

  • Is my tumor epithelial-dominant, sarcoma-dominant, or truly mixed — and how does that affect treatment options?
  • How aggressive is my specific case based on stage, grade, and pathology markers?
  • What is my likely prognosis, and how do factors like BRCA/HRD or complete cytoreduction influence survival?
  • Can cytoreductive surgery be complete (R0) or optimal in my case, and what risks are involved?
  • Should I seek surgery at a high-volume center experienced in ovarian carcinosarcoma?
  • If surgery is not possible, what other disease-control strategies are available?
  • If chemo is planned, which regimen is best for me — platinum/taxane (epithelial-leaning) or anthracycline/ifosfamide (sarcoma-leaning)?
  • How many cycles of chemotherapy are recommended, and what is the expected benefit?
  • What are the most common side effects of these regimens, and how are they managed?
  • If I become resistant to platinum, what other systemic therapies could be considered?
  • Have my tumor and blood been tested for BRCA, HRD, MSI/MMR, PD-L1, and HER2?
  • If I have BRCA or HRD, would a PARP inhibitor be an option?
  • If PD-L1 positive, could I qualify for immunotherapy or a clinical trial?
  • Are there other molecular alterations (like p53, PI3K/AKT/mTOR, CLDN18.2) that could influence future treatment?
  • Which clinical trials are available for ovarian carcinosarcoma or mixed Müllerian tumors?
  • Are there basket trials (based on biomarkers, not tumor type) that I might qualify for?
  • Do I need to travel to a major cancer center for these trials, or are there remote/affiliate sites?
  • How will we monitor whether treatment is working — imaging, CA-125, or symptoms?
  • How often will I need CT, MRI, or PET scans?
  • At what point would we decide to change or stop a therapy if it’s not working?
  • What supportive care options (pain, nutrition, exercise) can improve my tolerance to treatment?
  • Are there safe integrative or adjunctive therapies that might help without interfering with chemo?
  • What red flags should I watch for at home that mean I need urgent medical attention?
  • Are fertility or menopause issues relevant in my situation, and can they be managed alongside treatment?
  • What is the role of palliative care — should I start it now or later?
  • How do we balance aggressive treatment with quality of life?
  • What advance care planning steps should I consider while still pursuing treatment?

Find a trial

Search active and completed trials at these registries:

Citations

  1. Recent Developments in Rare Ovarian Carcinosarcoma: Literature Review (2025)

    PMC (Gynecologic Oncology Reports)

    • Epidemiology/rarity and prognosis
    • Rhabdomyosarcoma differentiation
    • Pathology markers (biphasic, p53, Ki-67)
    • Spread, staging, management
    • Targeted/immuno hooks (HRD/MSI)

  2. Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma (2022)

    Nature (British Journal of Cancer)

    • Overview: rare biphasic tumor; poor prognosis
    • Pathology markers; spread; advanced stage
    • Surgery/chemo; prognostic drivers

  3. Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management by PARP Inhibition and Immunotherapy (2024)

    PMC (Gynecologic Oncology)

    • Biomarkers: BRCA/HRD, MSI/MMR, PD-L1, HER2
    • Pathways: DNA repair, PI3K/AKT/mTOR, VEGF, PD-1/PD-L1
    • Targeted/immuno: PARP, IO; monitoring

  4. Predictive biomarkers for targeted therapy in daily anatomic pathology practice of ovarian cancer (2025)

    BMC Surgical & Experimental Pathology

    • Biomarkers: p53, ER/PR, BRCA/HRD, MSI, PD-L1, HER2, EGFR, Ki-67, p16
    • Markers: WT1, PAX8, cytokeratins, desmin, myogenin, vimentin

  5. Frontiers of Ovarian Carcinosarcoma (2023)

    Springer (Current Treatment Options in Oncology)

    • Epidemiology and prognosis
    • Pathways: EMT, hypoxia/HIF-1α, PI3K/AKT/mTOR, MMPs
    • Management: cytoreductive surgery, platinum/taxane; sarcoma regimens
    • VEGF/anti-angiogenic

  6. Ovarian Cancer Risk Factors (ACS, ongoing)

    American Cancer Society

    • Lifetime risk and risk factors
    • Presentations: bloating, satiety, urinary symptoms, ascites

  7. Ovarian Cancer: Symptoms, Diagnosis & Treatment (Cleveland Clinic, 2023)

    Cleveland Clinic

    • Symptoms and spread (pelvis, nodes, abdomen, intestines, liver, chest)

  8. Ovarian Cancer Staging (OCRA, ongoing)

    Ovarian Cancer Research Alliance

    • FIGO staging; prognosis by stage; surgery for staging/treatment

  9. Ovarian carcinosarcoma: Current developments and future perspectives (2019)

    Critical Reviews in Oncology/Hematology

    • Adjuncts (IVC, hyperthermia, curcumin, EGCG)
    • Contraindications & chemo timing/adjuncts

FAQs

Are there standard protocols for ovarian carcinosarcoma?
  • Care is individualized. Many plans adapt epithelial ovarian and sarcoma regimens based on pathology, biology, stage, and goals. High-volume centers and expert pathology review are valuable.
Is surgery (cytoreduction) always necessary or beneficial?
  • When feasible and safe, optimal cytoreduction can improve outcomes. Benefit depends on stage, distribution, and performance status. Ask whether your case is best served by upfront surgery or neoadjuvant therapy.
Which biomarkers actually matter for OCS?
  • Priority signals include HRD/BRCA, MSI/MMR, PD-L1 (contextual), and rare HER2 overexpression. p53 is almost always abnormal and explains aggressive biology but isn’t directly targetable yet.
How quickly does OCS adapt or become resistant?
  • OCS can pivot within weeks to months. Mechanisms include HR reversion (after PARP), pathway bypass (PI3K/AKT/MAPK), metabolic switching, immune escape (PD-L1 upregulation), and drug efflux.
Do adjuncts work on their own?
  • Adjuncts rarely control OCS alone. They’re best as synergy enhancers—timed around chemo, surgery, or trial agents. Without a cytotoxic or DNA-damaging backbone, adaptation often occurs within weeks.
How should I time adjuncts with chemotherapy?
  • Avoid antioxidant-heavy adjuncts on days when ROS-dependent chemo is given. Hold anti-angiogenic adjuncts in the peri-operative window (often ~2–4 weeks) unless cleared by your team.
Can cycling and multi-pathway strategies reduce resistance?
  • Yes. Alternating or combining pressure across pathways (DNA-damage, metabolic, immune, angiogenic) can limit escape. This must be planned to avoid overlapping toxicity and drug–drug interactions.
How do I tell if an adjunct is helping or hurting?
  • Change one variable at a time, define a short trial window (e.g., 2–4 weeks), track symptoms, labs, and any markers that were informative at baseline, and pre-define stop rules for side effects or no benefit.
Should I use CA-125 to track OCS?
  • Only if it was elevated at baseline and clearly tracks your disease. Otherwise, rely on symptoms, exam, and planned imaging intervals.
What is the role of PARP inhibitors?
  • Discuss if HRD/BRCA-positive and clinically appropriate (maintenance vs treatment settings). Monitor for fatigue, cytopenias, and GI effects; resistance can emerge via HR reversion.
Could immunotherapy help?
  • Benefit is more likely with MSI-H/dMMR or very high TMB; PD-L1 may aid trial eligibility. Responses are variable in OCS; immune-related adverse events require prompt reporting.
What about diet, fasting, or metabolic approaches?
  • Maintain weight and protein intake. If considering fasting/FMD, do so under supervision—avoid if underweight or frail. Metabolic strategies alone seldom control OCS; consider them as tolerance/synergy tools.
Which supplements are risky with my treatment?
  • Supplements that affect CYP3A4/P-gp, anticoagulation, QT interval, or platelet function can interact with chemo/targeted agents. Share a full list with your team and time them safely around infusions.
How often will I be monitored?
  • On active therapy, imaging is commonly every 8–12 weeks (individualize). Track symptoms closely and report changes early; spacing can lengthen on stable maintenance plans.
Should I get a second opinion or pathology review?
  • Yes, when feasible. Mixed histology can be challenging; expert pathology and a gynecologic oncology team can refine diagnosis and options.
How are ascites and pain managed?
  • Use multimodal symptom control. Paracentesis can relieve ascites; diuretics have limited benefit. Early palliative care consults improve quality of life and do not preclude active treatment.
How do clinical trials fit in?
  • Trials are key due to rarity and rapid adaptation. Ask about basket trials accepting HRD/BRCA, MSI-H/dMMR, PD-L1+, or HER2+ signal, and timing relative to lines of therapy.
What should I bring to visits?
  • A prioritized question list, current meds/supplements with doses, treatment side-effect log, goals of care, and a support person. Confirm what to do after-hours and which issues require the ER.
When do I call my team vs go to the ER?
  • Call urgently for red-flag symptoms; go to the ER for fever ≥100.4°F during chemo, chest pain or sudden shortness of breath, severe abdominal pain with no gas/stool, heavy bleeding, confusion, or seizure.

What we don't know yet

  • Few randomized trials specific to ovarian carcinosarcoma: most evidence is extrapolated from epithelial ovarian cancer or uterine carcinosarcoma cohorts.
  • Heterogeneous pathology and mixed histology complicate evidence synthesis: outcomes differ by epithelial vs sarcomatous predominance, but data are often pooled.
  • Limited biomarker-driven studies: BRCA/HRD, MSI, PD-L1, and HER2 testing are inconsistently reported, making it hard to know which subsets truly benefit from targeted or immunotherapies.
  • Small, retrospective case series dominate the literature: most reports have fewer than 50 patients, limiting statistical power and generalizability.
  • Lack of standardized adjunctive therapy evaluation: supportive and integrative strategies (IVC, hyperthermia, diet, supplements) are rarely studied in OCS specifically, leaving patients reliant on indirect evidence.
  • Minimal real-world registry data: population-based databases often underreport or misclassify OCS, making incidence, survival, and treatment-pattern estimates unreliable.
  • Sparse data on recurrence biology: little is known about how carcinoma vs sarcoma compartments evolve after therapy, or how best to target them at relapse.
  • Underrepresentation in clinical trials: most ovarian cancer trials exclude or fail to stratify carcinosarcoma, limiting insights into drug efficacy for this group.
  • No validated treatment algorithms unique to OCS: current guidelines default to high-grade serous ovarian carcinoma protocols, despite clear biological differences.
  • Outcome reporting inconsistency: survival, progression-free survival, and response metrics are often not stratified by histology, stage, or biomarker status, limiting precision in counseling patients.